Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 15, 2024

SELL
$2.29 - $4.48 $3,469 - $6,787
-1,515 Reduced 5.11%
28,148 $66,000
Q1 2024

May 07, 2024

SELL
$3.01 - $7.45 $47,762 - $118,216
-15,868 Reduced 34.85%
29,663 $156,000
Q4 2023

Feb 14, 2024

SELL
$1.4 - $3.24 $288,766 - $668,288
-206,262 Reduced 81.92%
45,531 $138,000
Q3 2023

Nov 14, 2023

SELL
$1.8 - $7.49 $186,762 - $777,139
-103,757 Reduced 29.18%
251,793 $453,000
Q2 2023

Aug 11, 2023

BUY
$4.3 - $9.48 $1.28 Million - $2.83 Million
298,399 Added 522.12%
355,550 $2.45 Million
Q1 2023

May 16, 2023

BUY
$4.81 - $8.88 $274,896 - $507,500
57,151 New
57,151 $354,000
Q3 2022

Nov 14, 2022

SELL
$7.57 - $12.5 $29,258 - $48,312
-3,865 Reduced 20.67%
14,837 $115,000
Q2 2022

Aug 15, 2022

SELL
$5.04 - $9.48 $124,966 - $235,056
-24,795 Reduced 57.0%
18,702 $143,000
Q1 2022

May 16, 2022

SELL
$7.09 - $89.45 $115,219 - $1.45 Million
-16,251 Reduced 27.2%
43,497 $336,000
Q4 2021

Feb 14, 2022

SELL
$80.85 - $128.49 $2.13 Million - $3.39 Million
-26,394 Reduced 30.64%
59,748 $5.07 Million
Q3 2021

Nov 15, 2021

BUY
$81.97 - $106.94 $1.62 Million - $2.11 Million
19,759 Added 29.77%
86,142 $8.27 Million
Q2 2021

Aug 11, 2021

BUY
$77.2 - $126.54 $4.14 Million - $6.79 Million
53,639 Added 420.9%
66,383 $6.17 Million
Q1 2021

May 17, 2021

BUY
$110.45 - $164.47 $632,105 - $941,261
5,723 Added 81.51%
12,744 $1.45 Million
Q4 2020

Feb 16, 2021

SELL
$60.78 - $154.03 $315,205 - $798,799
-5,186 Reduced 42.48%
7,021 $1.03 Million
Q3 2020

Nov 16, 2020

BUY
$45.05 - $59.27 $80,189 - $105,500
1,780 Added 17.07%
12,207 $723,000
Q2 2020

Aug 14, 2020

SELL
$42.74 - $66.25 $197,031 - $305,412
-4,610 Reduced 30.66%
10,427 $564,000
Q1 2020

May 15, 2020

BUY
$38.18 - $73.95 $176,315 - $341,501
4,618 Added 44.32%
15,037 $717,000
Q3 2019

Nov 14, 2019

BUY
$10.24 - $17.57 $106,690 - $183,061
10,419 New
10,419 $150,000

Others Institutions Holding KOD

About Kodiak Sciences Inc.


  • Ticker KOD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,040,200
  • Market Cap $288M
  • Description
  • Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as we...
More about KOD
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.